The pharma wholesale and distribution market is estimated to grow at a CAGR of 5.6% in the first half of the forecast period. The market is estimated to reach a revenue of $1.3bn in 2023. In 2017, the branded drugs submarket held 79% of the pharma wholesale and distribution market.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 277-page report you will receive 93 tables and 107 figures– all unavailable elsewhere.
The 277-page report provides clear detailed insight into the pharma wholesale and distribution market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Pharma Wholesale and Distribution Market from 2018-2028
• Forecast of the Global Pharma Wholesale and Distribution market by Category:
• Generic Drugs
• Branded Drugs
• Others
• This report provides individual revenue forecasts to 2028 for these national markets:
• US
• Germany
• France
• Italy
• Spain
• UK
• Japan
• China
• Brazil
• India
• Russia
• RoW
Each National Market is further segmented into generic drugs, branded drugs and others
• Our study discusses the selected leading companies that are the major players in the global pharma and wholesale distribution market:
• Alfresa Holdings
• AmerisourceBergen
• Cardinal Health
• McKesson
• Medipal
• PHOENIX Group
• Shanghai Pharma
• SINOPHARM
• Suzuken
• Walgreens Boots Alliance
• This report provides a SWOT and STEP analysis of the pharma wholesale and distribution market.
Visiongain’s study is intended for anyone requiring commercial analyses for the pharma wholesale and distribution market. You find data, trends and predictions.
Buy our report today Pharma Wholesale and Distribution Market Forecasts 2018-2028: Branded Drugs, Generic Drugs, US, China, Japan, Germany, France, Brazil, Italy, Spain, UK, India, Russia, RoW.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Global Pharma Wholesale and Distribution Industry and Market Overview
1.2 Benefits of This Report
1.3 How This Report Delivers
1.4 Questions Answered by This Analytical Report
1.5 Who is This Report For?
1.6 Methodology
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2. Introduction to Pharma Wholesale and Distribution
2.1 The Role of Pharmaceutical Wholesalers: The Middlemen of the Pharmaceutical Industry
2.1.1 Full-Line Wholesalers (FLWs)
2.1.2 Short-Line Wholesalers (SLWs)
2.2 The Chain of Distribution: Wholesalers vs. Logistic Service Providers
2.2.1 Secondary Wholesalers
2.2.2 Direct-to-Pharmacy (DTP) Distribution is Becoming More Prevalent
2.2.3 Major Wholesalers: Distribution of a Large Number of Products to Generate High Profits
2.2.4 Distribution from Large to Small Wholesalers: A Lengthy Distribution Chain
2.2.5 Pharmacy Benefit Managers
2.3 Generative Revenue and Profit
2.3.1 Forward Buying to Avoid Price Increases
2.3.2 Fee-for-Service: A Clear Pricing Structure
2.3.2.1 Inventory Management Agreements
2.3.3 Discounts: Incentives for Prompt Payment or Bulk Purchases
2.3.4 Reimbursement and Wholesalers
2.3.5 Clawback: The Recovery of Reimbursement Costs by Governments
2.3.6 Parallel Trade: Different Attitudes in Europe and the US
3. The World Pharmaceutical Wholesale and Distribution Market: 2017-2028
3.1 The World Pharmaceutical Wholesale and Distribution Market in 2017, Restricted by Government Price Reductions and Generic Substitution
3.2 The Pharmaceutical Wholesale and Distribution Industry: World Market Forecast, 2017-2028
3.3 Branded and Generic Drugs: Revenue vs. Profit, 2017-2028
3.3.1 Branded and Generic Drugs: Revenue Generation, 2017
3.3.2 Branded Drugs: Revenue Forecast, 2017-2028
3.3.3 Generic Drugs: Revenue Forecast, 2017-2028
4. Pharmaceutical Wholesale and Distribution Industry: Leading National Markets, 2017-2028
4.1 The Leading National Markets: the US Dominates in 2017
4.2 The Future of the Leading National Markets: Will the US Continue to Dominate the Market?
4.3 The US Pharma Wholesale and Distribution Market
4.3.1 The Budget Control Act and its Effect on the US Wholesale and Distribution Industry
4.3.2 Legislation to Prevent Counterfeit Drugs Can Differ Between States
4.3.3 An Increase in Fee-For-Service Activity
4.3.4 Pharma Wholesale and Distribution Market in the US: Market Forecast, 2017-2028
4.4 The Leading European (EU5) Pharma Wholesale and Distribution Markets
4.4.1 The Difference Between the US and European Markets
4.4.2 State-Funded Healthcare and Reimbursement
4.4.3 EU5: Market Forecast, 2017-2028
4.4.4 Germany: Pharma Wholesale and Distribution Market, 2017
4.4.4.1 Healthcare Reform
4.4.4.2 Germany: Reform of AMNOG Pharmaceutical Rebate Law
4.4.4.3 Germany Pharma Wholesale and Distribution Market Forecast, 2017-2028
4.4.5 France: Pharma Wholesale and Distribution Market, 2017
4.4.5.1 France: Social Security Finance Bill 2015
4.4.5.2 France: Pharma Wholesale and Distribution Market Forecast, 2017-2028
4.4.6 Italy: Pharma Wholesale and Distribution Market, 2017
4.4.6.1 Italy: Pharma Wholesale and Distribution Market Forecast, 2017-2028
4.4.7 Spain: Pharma Wholesale and Distribution Market, 2017
4.4.7.1 Spain: Pharma Wholesale and Distribution Market Forecast, 2017-2028
4.4.8 UK: Pharma Wholesale and Distribution Market, 2017
4.4.8.1 Price Cuts in the UK
4.4.8.2 UK: Pharma Wholesale and Distribution Market Forecast, 2017-2028
4.5 Japan: Pharma Wholesale and Distribution Market, 2017
4.5.1 Drug Pricing and Performing Fees in Japan
4.5.2 Japan: Pharma Wholesale and Distribution Market Forecast, 2017-2028
4.6 China: Pharma Wholesale and Distribution Market, 2017
4.6.1 China: Leading Pharma Wholesale and Distribution Companies, 2017
4.6.2 China: Pharma Wholesale and Distribution Market Forecast, 2017-2028
4.7 Brazil: Pharma and Wholesale Distribution Market, 2017
4.7.1 Drug Price Controls in Brazil
4.7.2 Brazil: Leading Pharma Wholesale and Distribution Companies, 2017
4.7.3 Brazil: Pharma Wholesale and Distribution Market Forecast, 2017-2028
4.8 India: Pharma Wholesale and Distribution Market, 2017
4.8.1 India: Pharma Wholesale and Distribution Market Forecast, 2017-2028
4.9 Russia: Pharma Wholesale and Distribution Market, 2016
4.9.1 Drug Pricing Controls in Russia
4.9.2 Market Trends in Russia
4.9.3 Russia: Pharma Wholesale and Distribution Market Forecast, 2017-2028
4.10 Conclusion
5. Leading Pharma Wholesalers and Distributors In 2016: Current and Future Performance
5.1 The Leading Pharma Wholesalers and Distribution Companies in 2017
5.2 Revenue vs. Profit
5.3 Leading Pharma Wholesale and Distribution Companies: Grouped Forecasts, 2017-2028
5.4 McKesson: The Oldest and Largest Healthcare Services Company in the US
5.4.1 McKesson: Historical Performance, 2011-2016
5.4.2 Future Strategies: Consummate Acquisitions to Complement Existing Business or Expand Businesses
5.4.3 McKesson: Revenue Forecast, 2017-2028
5.5 Cardinal Health: The World’s Third Largest Pharma Wholesaler
5.5.1 Cardinal Health: Historical Performance, 2011-2016
5.5.2 Will CVS Joint Venture and Acquisitions Stimulate Future Growth?
5.5.3 Cardinal Health: Revenue Forecast, 2017-2028
5.6 AmerisourceBergen: Third Largest Global Pharma Wholesaler and Distributor
5.6.1 AmerisourceBergen: Historical Performance, 2016
5.6.2 Will Contracts with Walgreens and Alliance Boots Drive Future Growth?
5.6.3 AmerisourceBergen: Revenue Forecast, 2017-2028
5.7 Walgreens Boots Alliance: The Largest Drugstore Chain in the US and Global Wholesale and Distribution Network
5.7.1 Walgreens Boots Alliance: Historical Performance, 2011-2016
5.7.2 Acquisitions and Future Strategies of Walgreens Boots Alliance
5.7.3 Walgreens Boots Alliance: Revenue Forecast, 2017-2028
5.8 MEDIPAL HOLDINGS CORPORATION: Japan’s Leading Pharmaceutical Wholesaler
5.8.1 MEDIPAL HOLDINGS CORPORATION: Historical Performance, 2011-2016
5.8.2 Future Strategies of MEDIPAL HOLDINGS CORPORATION: Revised Business Portfolio with Diverse Sources of Earnings
5.8.3 MEDIPAL HOLDINGS CORPORATION: Revenue Forecast, 2017-2028
5.9 Phoenix Group: Biggest European Wholesalers
5.9.1 The PHOENIX Group: Historical Performance, 2011-2016
5.9.2 Future Strategies of the PHOENIX Group: Selective Acquisition
5.9.3 The PHOENIX Group: Revenue Forecast, 2017-2028
5.10 SINOPHARM: The Leading Pharmaceutical Wholesaler and Distributor in China
5.10.1 SINOPHARM: Historical Performance, 2011-2016
5.10.2 Future Strategies of SINOPHARM: Provide Comprehensive Services and Wider Business Coverage
5.10.3 SINOPHARM: Revenue Forecast, 2017-2028
5.11 Alfresa Holdings: Second Largest Pharmaceutical Wholesaler and Distributor in Japan
5.11.1 Alfresa Holdings: Historical Performance, 2011-2016
5.11.2 Future Strategy of Alfresa Holdings: To Focus on Expanding Business Fields and Increasing Footprint
5.11.3 Alfresa Holdings: Revenue Forecast, 2017-2028
5.12 SUZUKEN CO., LTD: The First Nationwide Wholesaler of Japan
5.12.1 SUZUKEN CO. LTD: Historical Performance, 2011-2016
5.12.2 Future Strategies of SUZUKEN CO., LTD: Five Growth Initiatives and Special Focus on Diabetes Field
5.12.3 SUZUKEN CO., LTD: Revenue Forecast, 2017-2028
5.13 Shanghai Pharmaceuticals Holding: China’s Second Largest Wholesaler
5.13.1 Shanghai Pharmaceuticals Holding: Historical Performance, 2011-2016
5.13.2 Future Strategies of Shanghai Pharma: Expansion of Three Leading Regions in China
5.13.3 Shanghai Pharma: Revenue Forecast, 2017-2028
6. Qualitative Analysis of the Pharma Wholesale and Distribution Market
6.1 The Strengths and Weaknesses of the Pharma Wholesale and Distribution Market, 2017
6.1.1 The Insatiable Demand for Drugs: A Recession Proof Industry?
6.1.2 Wholesalers Do More than Deliver Drugs
6.1.2.1 Pre-Wholesaling: More Prevalent in Europe
6.1.2.2 Through Pre-Financing, Full-Line Wholesalers Finance the Entire Medicines Market
6.1.3 Large Companies Dominate the Market
6.1.4 Despite High Revenues, Profit Margins Are Low
6.1.5 Government-Induced Drug Price Pressures Restrict Profits
6.1.6 The Problem of Counterfeit Drugs
6.2 The Opportunities and Threats of the Pharma Wholesale and Distribution Market, 2017-2028
6.2.1 The Demand for Pharmaceuticals is Increasing
6.2.2 The Increasing Use of Specialty Drugs Will Drive Growth
6.2.3 The Increasing Use of Generic Drugs Will Limit Revenue but Drive Profit Generation
6.2.4 The Promotion of Drug Therapy in the US
6.2.5 Globalisation: The Major National Markets are Dominated by Few Companies
6.2.6 Increased Adoption of the DTP Distribution Model
6.2.6.1 DTP in Europe: The First Place the Scheme Has Taken Hold
6.2.6.2 DTP in the UK Since 1991
6.2.6.3 DTP in Poland: The Second European Country To Adopt the DTP Model
6.2.6.4 Further Expansion of the DTP Model
6.2.7 The Threat of Healthcare Budget Cuts
6.2.7.1 Healthcare Budget Cuts in Germany
6.2.7.2 Healthcare Budget Cuts in France
6.2.7.3 Healthcare Budget Cuts in Italy
6.2.7.4 Healthcare Budget Cuts in Spain
6.2.7.5 Healthcare Budget Cuts in the UK
6.2.8 Do Large Pharmacy Chains Pose a Threat?
6.2.8.1 Case Study: Walmart and the $4 Prescription Scheme
6.2.8.2 Vertical Integration of Wholesalers: A Response to the Threat of Pharmacy Chains
6.2.9 Does the Diversion and Re-Importation of Medicines Pose a Threat to the Industry?
6.2.10 The Threat of Industry Consolidation
6.3 Social, Technological, Economic and Political Factors Influencing the Market, 2017-2028 (STEP Analysis)
6.3.1 Political Factor: The Impact of Recent Regulatory Changes in the EU
6.3.2 Political Factor: Combating Counterfeit Medicines
6.3.2.1 The US and E-Pedigree: Becoming Law in California
6.3.2.2 European Pedigree Legislation
6.3.2.3 Anti-Counterfeiting Strategies in Other Markets: The Chinese Government is Attempting to Address the Challenge
6.3.2.4 Serialisation for Wholesalers: Opportunity or a Challenge?
7. Conclusions
7.1 The Future of the Pharma Wholesale and Distribution Market
7.2 The Leading National Pharma Wholesale and Distribution Markets
7.3 The Leading Companies in the Pharma Wholesale and Distribution Industry
7.4 Trends in the Pharma Wholesale and Distribution Industry
7.4.1 Generics Will Threaten Revenue
7.4.2 Manufacturers Will Deliver More Drugs Directly
7.4.3 There Will Be Greater Demand for Specialty Medicines
7.4.4 Consolidation Will Drive Growth
7.4.5 Anti-Counterfeiting Demands Will Add to Wholesalers’ Costs
Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
List of Tables
Table 2.1 Use of DTP Model in the UK, 2007-2012
Table 3.1 Pharmaceutical Wholesale and Distribution: World Market Forecast ($bn), AGR (%), CAGR (%), 2017-2028
Table 3.2 Pharmaceutical Wholesale and Distribution: Branded Drugs, Generic Drugs and Others, Revenue ($bn) Forecasts, AGR (%), CAGR (%) and Market Shares (%), 2017-2028
Table 3.3 Wholesale and Distribution of Branded Drugs: Revenue ($bn) and Market Share (%) Forecast, 2017-2028
Table 3.4 Wholesale and Distribution of Generic Drugs: Revenue ($bn) and Market Share (%) Forecast, 2017-2028
Table 4.1 Pharma Wholesale & Distribution Leading National Markets: Revenues ($bn) and Market Share (%), 2017
Table 4.2 Pharma Wholesale & Distribution Leading National Markets: Revenue ($bn) Forecasts, AGR (%) and CAGR (%), 2017-2028
Table 4.3 US Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028
Table 4.4 Us Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, AGR (%) And CAGR (%), 2017-2028
Table 4.5 Price Controls in Europe, 2016
Table 4.6 EU5 Pharma Wholesale & Distribution Market: Revenue ($bn) Forecasts, AGR (%) and CAGR (%), 2017-2028
Table 4.7 German Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028
Table 4.8 German Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028
Table 4.9 French Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028
Table 4.10 French Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028
Table 4.11 Italian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028
Table 4.12 Italian Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028
Table 4.13 Spanish Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028
Table 4.14 Spanish Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028
Table 4.15 UK Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028
Table 4.16 UK Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028
Table 4.17 Percentage of The Population Ages 60+ In the Us, Europe, Japan, China and India, 2015 And 2030
Table 4.18 Japanese Pharmaceutical Wholesale and Distribution Market: Drug Price Revision Growth (%), 2007-2017
Table 4.19 Japanese Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028
Table 4.20 Japanese Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028
Table 4.21 Chinese Pharma Wholesale & Distribution: Revenue ($bn) And Market Shares (%) of Leading Companies, 2017
Table 4.22 Chinese Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028
Table 4.23 Chinese Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028
Table 4.24 Brazilian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028
Table 4.25 Brazilian Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028
Table 4.26 Indian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028
Table 4.27 Indian Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028
Table 4.28 Russian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2017-2028
Table 4.29 Russian Pharma Wholesale & Distribution Market: Revenue ($Bn) Forecast, AGR (%) and CAGR (%), 2017-2028
Table 5.1 Leading Companies in The Pharmaceutical Wholesale and Distribution Market: Revenues ($bn) and Market Shares (%), 2017
Table 5.2 Leading Pharmaceutical Wholesale and Distribution Companies: Revenue Forecasts ($bn), AGR (%) and CAGR (%), 2017-2028
Table 5.3 Leading Pharmaceutical Wholesale and Distribution Companies: Market Shares (%) for 2017, 2022 And 2028
Table 5.4 Mckesson, Distribution Solutions: Services and Customers, 2017
Table 5.5 Mckesson, Technology Solutions: Services and Customers, 2017
Table 5.6 Mckesson: Historical Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit ($bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2016
Table 5.7 Mckesson: Revenue ($bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2016-2017
Table 5.8 Mckesson: Gross Profit ($bn), Gross Profit Share (%) and AGR (%) Breakdown by Business Segment, 2016-2017
Table 5.9 Acquisitions by Mckesson, 2007-2018
Table 5.10 Mckesson: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2017-2028
Table 5.11 Cardinal Health: Historical Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Operating Earnings ($bn), AGR (%) and CAGR (%), 2010-2015
Table 5.12 Cardinal Health: Revenue ($bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2016-2017
Table 5.13 Cardinal Health: Operating Earnings ($bn) and Annual Growth (%) Breakdown by Business Segment, 2016-2017
Table 5.14 Cardinal Health: Revenue ($bn) And Revenue Share (%) Breakdown by Customer, 2017
Table 5.15 Selected Acquisitions by Cardinal Health and Their Line of Business, 2007-2018
Table 5.16 Cardinal Health: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2017-2028
Table 5.17 Amerisourcebergen: Historical Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit ($bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2016
Table 5.18 Amerisourcebergen: Revenue ($bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2016-2017
Table 5.19 Amerisourcebergen: Gross Profit ($bn), Gross Profit Share (%) and AGR (%) Breakdown by Business Segment, 2016-2017
Table 5.20 Amerisourcebergen: Revenue ($bn) and Revenue Share (%) Breakdown by Customer, 2017
Table 5.21 Acquisitions by Amerisourcebergen and Their Line of Business, 2007-2018
Table 5.22 Amerisourcebergen: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2017-2028
Table 5.23 Walgreens Boots Alliance: Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit ($bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2016
Table 5.24 Walgreens Boots Alliance: Pharmaceutical Wholesale Revenue ($bn), AGR (%), and CAGR (%) Forecast, 2017-2028
Table 5.25 Medipal Holdings: Consolidated Subsidiary Companies, 2017
Table 5.26 Medipal Holdings: Historical Revenue (¥bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (¥bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2016
Table 5.27 Medipal Holdings: Revenue (¥bn, $bn) and Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2016-2017
Table 5.28 Medipal Holdings: Operating Income ($bn, ¥bn), Operating Income Share (%) and AGR (%) Breakdown by Business Segment, 2016-2017
Table 5.29 Medipal Holdings: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2017-2028
Table 5.30 Phoenix Group: Subsidiary Companies, 2017
Table 5.31 Phoenix Group: Historical Revenue (€bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (€bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2016
Table 5.32 Phoenix Group: Revenue (€bn, $bn), Revenue Share (%) Breakdown by Region, 2017
Table 5.33 Phoenix Group: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2017-2028
Table 5.34 Sinopharm Group: Historical Revenue (RMBbn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (RMBbn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2016
Table 5.35 Sinopharm Group: Revenue (RMBbn, $bn) and Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2016-2017
Table 5.36 Sinopharm Group: Operating Profit (RMBbn, $bn), Operating Profit Share (%) and AGR (%) Breakdown by Business Segment, 2015-2016
Table 5.37 Sinopharm Group: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2017-2028
Table 5.38 Alfresa Holdings: List of Significant Subsidiaries and Affiliates, 2017
Table 5.39 Alfresa Holdings: Historical Revenue (¥bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (¥bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2016
Table 5.40 Alfresa Holdings: Business Strategies, 2013-2017
Table 5.41 Alfresa Holdings: Revenue (¥bn, $bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2016-2017
Table 5.42 Alfresa Holdings: Gross Profit (¥bn, $bn), Gross Profit Share (%) and AGR (%) Breakdown by Business Segment, 2016-2017
Table 5.43 Alfresa Holdings: Challenges for the 16-18 Mid-Term Management Plan - Break Through to Tomorrow, 2016
Table 5.44 Alfresa Holdings: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2017-2028
Table 5.45 Suzuken: Historical Revenue (¥bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (¥bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2016
Table 5.46 Suzuken: Revenue (¥bn, $bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2015-2016
Table 5.47 Suzuken: Operating Income (¥bn, $bn), Operating Income Share (%) and AGR (%) Breakdown by Business Segment, 2015-2016
Table 5.48 Suzuken: Revenue (¥bn, $bn), Revenue Share (%) Breakdown for Pharmaceuticals Distribution Segment by Region, 2014
Table 5.49 Suzuken: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2017-2028
Table 5.50 Shanghai Pharmaceuticals Holding: Historical Revenue (RMBbn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (RMBbn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2016
Table 5.51 Shanghai Pharmaceuticals Holding: Revenue (RMBbn, $bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2015-2016
Table 5.52 Shanghai Pharmaceuticals Holding: Operating Profit (RMBbn, $bn), Operating Profit Share (%) and AGR (%) Breakdown by Business Segment, 2015-2016
Table 5.53 Shanghai Pharmaceuticals Holding: Distribution Revenue (RMBbn, $bn), Distribution Revenue Share (%) Breakdown by Region, 2016
Table 5.54 Shanghai Pharmaceuticals Holding: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2017-2028
Table 6.1 The Pharmaceutical W&D Market: Strengths and Weaknesses, 2017
Table 6.2 The Pharmaceutical W&D Market: Opportunities and Threats, 2017-2028
Table 6.3 Strengths and Weaknesses of The DTP Distribution Model, 2017
Table 6.4 ITR Ratings and Corresponding Reimbursement Rates, 2017
Table 6.5 Social, Technological, Economic and Political Factors Influencing the Pharmaceutical Wholesale and Distribution Market (Step Analysis), 2017-2028
List of Figures
Figure 2.1 Routes of Drug Distribution, 2017
Figure 3.1 The Global Pharmaceutical Wholesale and Distribution Market: Drivers and Restraints, 2017
Figure 3.2 Pharmaceutical Wholesale and Distribution: World Market Forecast ($Bn), 2017-2028
Figure 3.3 Branded Drugs, Generic Drugs and Others: Market Shares (%), 2017
Figure 3.4 Pharmaceutical Wholesale and Distribution: World Market Forecast ($Bn) By Category, 2017-2028
Figure 3.5 Branded Drugs, Generic Drugs and Others: Market Shares (%), 2023
Figure 3.6 Branded Drugs, Generic Drugs and Others: Market Shares (%), 2028
Figure 3.7 Wholesale and Distribution of Branded Drugs, Generic Drugs and Others: Revenue Forecasts ($bn), 2017-2028
Figure 3.8 Wholesale and Distribution of Branded Drugs: Revenue ($bn) Forecast, 2017-2028
Figure 3.9 Wholesale and Distribution of Generic Drugs: Revenue ($bn) Forecast, 2017-2028
Figure 4.1 Pharma Wholesale & Distribution Leading National Markets: Shares (%), 2017
Figure 4.2 Pharma Wholesale & Distribution Leading National Markets: Shares (%), 2023
Figure 4.3 Pharma Wholesale & Distribution Leading National Markets: Shares (%), 2028
Figure 4.4 Market Share (%) Breakdown of The Us Market: The 3 Leading Companies, 2017
Figure 4.5 US Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2017-2028
Figure 4.6 US Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, 2017-2028
Figure 4.7 US Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
Figure 4.8 EU5 Pharma Wholesale & Distribution Market Shares (%), 2017, 2023 And 2028
Figure 4.9 EU5 Pharma Wholesale & Distribution Market: Revenue ($bn) Forecasts, 2017-2028
Figure 4.10 EU Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
Figure 4.11 German Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2017-2028
Figure 4.12 German Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($Bn) Forecast, 2017-2028
Figure 4.13 German Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
Figure 4.14 French Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2017-2028
Figure 4.15 French Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, 2017-2028
Figure 4.16 French Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
Figure 4.17 Italian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2017-2028
Figure 4.18 Italian Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, 2017-2028
Figure 4.19 Italian Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
Figure 4.20 Spanish Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2017-2028
Figure 4.21 Spanish Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, 2017-2028
Figure 4.22 Spanish Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
Figure 4.23 UK Pharma Wholesale & Distribution Market: Revenue ($bn), 2017-2028
Figure 4.24 UK Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, 2017-2028
Figure 4.25 UK Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
Figure 4.26 Percentage of The Population Ages 65+ in the Us, Europe, Japan, China and India, 2015 And 2030
Figure 4.27 Japanese Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2017-2028
Figure 4.28 Japanese Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, 2017-2028
Figure 4.29 Japanese Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
Figure 4.30 Chinese Pharma Wholesale & Distribution: Market Shares (%) of Leading Companies, 2017
Figure 4.31 Chinese Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2017-2028
Figure 4.32 Chinese Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, 2017-2028
Figure 4.33 Chinese Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
Figure 4.34 Brazilian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2017-2028
Figure 4.35 Brazilian Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, 2017-2028
Figure 4.36 Brazilian Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
Figure 4.37 Pharma Wholesale & Distribution Model in India, 2017
Figure 4.38 Indian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2017-2028
Figure 4.39 Indian Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($bn) Forecast, 2017-2028
Figure 4.40 Indian Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
Figure 4.41 Russian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2017-2028
Figure 4.42 Russian Pharma Wholesale & Distribution Market by Drugs Category: Revenue ($Bn) Forecast, 2017-2028
Figure 4.43 Russian Pharma Wholesale & Distribution Market: Drivers and Restraints, 2017
Figure 5.1 Leading Pharmaceutical Wholesale and Distribution Companies: Market Shares (%), 2017
Figure 5.2 Leading Pharmaceutical Wholesale and Distribution Companies: Market Shares (%), 2023
Figure 5.3 Leading Pharmaceutical Wholesale and Distribution Companies: Market Shares (%), 2028
Figure 5.4 Leading Pharmaceutical W&D Companies: Drivers and Restraints, 2017
Figure 5.5 Mckesson: Historical Revenue ($bn), Revenue AGR (%), Gross Profit ($bn) And Gross Profit AGR (%), 2011-2016
Figure 5.6 Mckesson: Revenue Share (%) Breakdown by Business Segment, 2016
Figure 5.7 Mckesson: Revenue Share (%) Breakdown by Business Segment, 2017
Figure 5.8 Mckesson: Revenue ($bn) Forecast, 2017-2028
Figure 5.9 Mckesson: Drivers and Restraints, 2017
Figure 5.10 Cardinal Health: Historical Revenue ($bn), Revenue AGR (%), Operating Earnings ($bn) and Operating Earnings AGR (%), 2011-2016
Figure 5.11 Cardinal Health: Revenue Share (%) Breakdown by Business Segment, 2017
Figure 5.12 Cardinal Health: Revenue Share (%) Breakdown by Customer, 2017
Figure 5.13 Cardinal Health: Revenue ($bn) Forecast, 2017-2028
Figure 5.14 Cardinal Health: Drivers and Restraints, 2017-2028
Figure 5.15 Amerisourcebergen: Historical Revenue ($bn), Revenue AGR (%), Gross Profit ($bn) and Gross Profit AGR (%), 2011-2016
Figure 5.16 Amerisourcebergen: Revenue Share (%) Breakdown by Business Segment, 2017
Figure 5.17 Amerisourcebergen: Revenue ($bn) Breakdown by Customer, 2017
Figure 5.18 Amerisourcebergen: Revenue ($bn) Forecast, 2017-2028
Figure 5.19 Amerisourcebergen: Drivers and Restraints, 2017
Figure 5.20 Walgreens Boots Alliance: Revenue ($bn), Revenue AGR (%), Gross Profit ($bn) and Gross Profit AGR (%), 2011-2016
Figure 5.21 Walgreens Boots Alliance: Revenue ($bn) Forecast, 2017-2028
Figure 5.22 Alliance Boots: Drivers and Restraints, 2017-2028
Figure 5.23 Medipal Holdings: Historical Revenue (¥bn), Revenue AGR (%), Gross Profit (¥bn) and Gross Profit AGR (%), 2011-2016
Figure 5.24 Medipal Holdings: Revenue Share (%) Breakdown by Business Segment, 2016
Figure 5.25 Medipal Holdings: Operating Income Share (%) Breakdown by Business Segment, 2017
Figure 5.26 Medipal Holdings: Revenue ($bn) Forecast, 2017-2028
Figure 5.27 Medipal Holdings: Drivers and Restraints, 2017
Figure 5.28 Phoenix Group: Historical Revenue (€bn), Revenue AGR (%), Gross Profit (€bn) and Gross Profit AGR (%), 2011-2016
Figure 5.29 Phoenix Group: Revenue Share (%) Breakdown by Region, 2014
Figure 5.30 Phoenix Group: Revenue ($bn) Forecast, 2017-2028
Figure 5.31 Phoenix Group Drivers and Restraints, 2017
Figure 5.32 Sinopharm Group: Historical Revenue (RMBbn), Revenue AGR (%), Gross Profit (RMBbn) and Gross Profit AGR (%), 2011-2016
Figure 5.33 Sinopharm Group: Revenue ($bn) Forecast, 2017-2028
Figure 5.34 Sinopharm Group: Drivers and Restraints, 2017
Figure 5.35 Alfresa Holdings: Historical Revenue (¥bn), Revenue AGR (%), Gross Profit (¥bn), Gross Profit AGR (%), 2011-2016
Figure 5.36 Alfresa Holdings: Revenue Share (%) Breakdown by Business Segment, 2016
Figure 5.37 Alfresa Holdings: Gross Profit Share (%) Breakdown by Business Segment, 2017
Figure 5.38 Alfresa Holdings: Revenue ($bn) Forecast, 2017-2028
Figure 5.39 Alfresa Holdings: Drivers and Restraints, 2017
Figure 5.40 Suzuken: Historical Revenue (¥bn), Revenue AGR (%), Gross Profit (¥bn) and Gross Profit AGR (%), 2011-2016
Figure 5.41 Suzuken: Revenue Share (%) Breakdown by Business Segment, 2015
Figure 5.42 Suzuken: Operating Income Share (%) Breakdown by Business Segment, 2016
Figure 5.43 Suzuken: Revenue Share (%) Breakdown by Region in Japan, 2014
Figure 5.44 Suzuken: Revenue ($bn) Forecast, 2017-2028
Figure 5.45 Suzuken: Drivers and Restraints, 2017
Figure 5.46 Shanghai Pharmaceuticals Holding: Historical Revenue (RMBbn), Revenue AGR (%), Gross Profit (RMBbn) and Gross Profit AGR (%), 2011-2016
Figure 5.47 Shanghai Pharmaceuticals Holding: Revenue Share (%) Breakdown by Business Segment, 2016
Figure 5.48 Shanghai Pharmaceuticals Holding: Revenue Share (%) Breakdown by Region, 2016
Figure 5.49 Shanghai Pharmaceuticals Holding: Revenue ($bn) Forecast, 2017-2028
Figure 5.50 Shanghai Pharmaceuticals Holding: Drivers and Restraints, 2017
Figure 6.1 Comparison of The Wholesale and DTP Routes of Distribution, 2017
Figure 7.1 Pharmaceutical Wholesale and Distribution: Global Market Forecasts ($Bn) By Submarket, 2017-2028
Figure 7.2 Leading National Pharmaceutical Wholesale and Distribution Markets: Revenue Projections ($Bn), 2017, 2022 And 2028
Figure 7.3 Leading Pharmaceutical Wholesale and Distribution Companies: Revenue ($Bn) Projections 2017, 2022 And 2028
36.6
AAH Pharmaceuticals
AccessClosure
Acofarma (Asociación Cooperativas Farmacéuticas)
ADG Apotheken-Dienstleistungsgesellschaft mbH
Admenta
Alfresa Fine Chemical Corporation
Alfresa Holdings
Alliance Boots
Alliance Healthcare
Alliance Santé
Alliance UniChem
AmeriSource Health
AmerisourceBergen
AmerisourceBergen Canada
AmerisourceBergen Drug Corporation (ABDC)
AmerisourceBergen specialty Group (ABSG)
Apollo Medical Holdings
ASTEC Co., Ltd.
ASTIS Co., Ltd.
Athos Farma
ATOL CO., LTD.
Azwell
Bayer
BENU Apotheek
Bergen Brunswig
Biologics Inc
Boots Group
Bristol-Myers Squibb
Brocacef Groep NV
Brocacef Holding
Bundesverband des Pharmazeutischen Grosshandel
Cardinal Health
Caremark Rx
Celesio AG
CERP Bretagne Nord
CERP Rhin Rhone Mediterranee
CERP Rouen
Chiyaku Co
Chuounyu Co., Ltd.
Cloumed Corporation
Cofares
Comifar
Cordis
CoverMyMeds
CoverMyMeds LLC
CVS Caremark
CVS Corporation
CVS Health Corporation
Cystic Fibrosis Foundation Pharmacy, LLC
Daiichi Sankyo Propharma Co.
Dong Ying (Jiangsu) Pharmaceuticals Co., Ltd.
Drogarias Tamoio
Drug Trading Company Ltd
Dutch ACM
Emart Company
ENSHU YAKUHIN CO., LTD.
Ethicon
EVERLTH AGROTECH Co., Ltd.
EVERLTH Co., Ltd.
Farcopa Distribuzione
Fukujin Co.
Good Service Co
Guangzhou Pharmaceutical Company Ltd.
Guangzhou Pharmaceuticals Corporation
Harvard Drug
Hedef Alliance
Hefame
HEISEI YAKUHIN CO., LTD.
IZUTSU KURAYA SANSEIDO Inc.
IZUTSU PHARMACEUTICAL CO. LTD.
Japanese Pharmaceutical Wholesalers Association
Jingu Yakuhin Co., Ltd.
Johnson & Johnson
Katren
Kenzmedico Co., Ltd.
Kerr Drug
KOBASHOU. CO., LTD.
KURAYA SANSEIDO Inc
Life Medicom Co., Ltd.
Lloyds Pharmacy
MARUZEN YAKUHIN CO., LTD.
McKesson
McQueary Brothers of Springfield
Medical Specialties Distributors
MEDICEO CORPORATION
Medicine Shoppe Canada Inc.
MEDIE Co., Ltd.
MEDIPAL HOLDINGS CORPORATION
Mediq Apotheken Nederland B.V.
Medtronic
Meinan Distribution Center
Metro Medical Supply Inc
Mitsubishi
MM CORPORATION
MP AGRO CO., LTD.
MVC CO., LTD
MWI Veterinary Supply, Inc.
Nadro
Nakano Yakuhin Co., Ltd.
National Health Service (NHS)
National Pharmaceutical Pricing Authority (NPPA)
Nihon Apoch Co.
Novo Nordisk
Novodata Zrt.
Numark
OCP
Oncology Therapeutics
Oncoprod
OptumRx
P.J.D. Network
PALTAC CORPORATION
Paltac Corporation
Paltac Corporation
PALTAC KS CORPORATION
Panpharma
Pfercos Co., Ltd.
Pfizer
PharMEDium
Polska Grupa Farmaceutyczna
Profarma
Prosper
Protek
PSC Co, Ltd.
PSS World Medical Inc.
Ratiopharm
RDC Kanto5
Red Oak Sourcing
Red Oak, LLC
Rexall Health
Rite Aid Corporation
Rosta
RxCrossroads
S. D.Collabo Co.,Ltd.
S.D.Logi CO., Ltd.
Sakurai Tsusho Corporation
Sanacorp
Sandoz
Sanki Corporation
Sanki MediHeart Limited
Sanki Wellbe
Sanki Wellbe Co., Ltd.
Sannova
Sanwa Kagaku Kenkyusho Co., Ltd.
S-Care Mate Co., Ltd.
Sciclone Trade
SEIWA SANGYO CO
Shanghai Fosun Pharmaceutical
Shanghai Pharma Zhenjiang Co., Ltd.
Shanghai Pharmaceutical Holdings
Shinohara Chemicals
Shinsegai Group
Shoyaku Co., Ltd.
SIA International
Sincamesp
SINOPHARM
S-mile, Inc
Sonexus Health
SPH Jiangxi Shangrao Pharmaceutical Co., Ltd.
SPH Keyuan Xinhai Pharmaceutical Hebei Co., Ltd.
SPH Keyuan Xinhai Pharmaceutical Heilongjiang Co., Ltd.
SPLine Corporation
SUZUKEN
Suzuken Co., Ltd.
Suzuken Iwate Co., Ltd.
Suzuken Medical Instruments Co, Ltd
Suzuken Okinawa Yakuhin Co., Ltd.
The PHOENIX Group
Toho Holdings
Tokiwa Yakuhin Co
Torfarm
Tradex International
TS Alfresa Corporation
UniChem
US Oncology Holdings, Inc.
USHIODA KURAYA SANSEIDO Inc.
USHIODA SANGOKUDO YAKUHIN CO., LTD.
Vaccine Safe Co
Vantage Oncology
Victoria Merger Sub, Inc.
Vitaco Holdings
Walgreen
Walgreens Boots Alliance
World Courier Group Inc.
Wyeth Pharmaceuticals
YAMAHIRO KURAYA SANSEIDO Inc.
Yunnan Pharmaceutical Co., Ltd.
Zuellig Pharma
